CTOs on the Move

C2i Genomics

www.c2i-genomics.com

 
C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor`s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

C2i Genomics raised $12M on 06/09/2020
C2i Genomics raised $100M on 04/15/2021

Similar Companies

Ludesi

Ludesi is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tarveda Therapeutics

Tarveda Therapeutics is a clinical stage biopharmaceutical company that takes a novel approach to cancer treatment by creating proprietary Pentarins, which are potent and selective, miniaturized conjugates uniquely designed to drive efficacy through deep and rapid penetration into solid tumors resulting in sustained payload accumulation and cancer cell death. Through our Pentarin platform, we are developing therapeutics to address the limitations of current cancer therapies in solid tumors.

BIND Therapueitics

BIND Therapueitics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Environmental Testing And Abatement

Advanced Environmental Testing And Abatement is a Waterloo, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GlycoMimetics

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow`s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company`s inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.